Ali Mortazavi, the chief executive of Silence Therapeutics (LON:SLN), discusses the £40mln conditional fundraising with Proactive Investors.
He reveals that institutional investors took part in the placing for £27.3mln, which is subject to shareholder approval. The amount raised could rise to £40mln or so if the demand is there, with an option granted to the joint bookrunners to find subscribers for an additional 5.3mln shares.
No comments:
Post a Comment
Commented on MasterMetals